Short-term risk and long-term incidence rate of infection and malignancy with IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis

**Study information**

Author: Shuwei Wu  
-Department of Dermatology, West China Hospital, Sichuan University, Chengdu 610041, China  
PROSPERO registration number: CRD42022363127

**Background**

The risk of infection and malignancy could be a major concern of psoriasis patients treated with IL-23 inhibitors, particularly those who receive long-term treatments.

**Objective**

Evaluate the short-term risk and long-term incidence rate (more than 52 weeks) of infection and malignancy with IL-23 inhibitors in adult patients with plaque psoriasis (PsO) and psoriatic arthritis (PsA).

**Results**

The present study included 14 randomized placebo-controlled studies (including 7,853 patients) and 9 extension trials (including 27440.2 patient-years, PYs). The pooled risk ratios (RRs) for short-term risk of serious infection or malignancy were not increased with IL-23 inhibitors, though overall infection was moderately increased. Long-term incidence rate was 1.09/100PYs of serious infection, 48.50/100PYs of overall infection, 0.40/100PYs of non-melanoma skin cancer (NMSC), and 0.54/100PYs of malignancies excluding NMSC. The incidence rates seemed not increased with the duration prolonged.

**Conclusion**

Our study supports that IL-23 inhibitors can be safely used for PsO and PsA, regardless of the treatment durations. However, careful monitoring is warranted for overall infection following IL-23 inhibitors.